Scan the QR code or go on to take a look at and get informed about Prof. Dr. Schuberts research on ORCID.




The laboratories of the Schubert group are equiped with the most advanced robotic platforms and high speed equipment. This leads to a perfect work environment and is concidered state of the art.

Take a look at the menu under "facilities" for a detailed view and information about the equipment.

Prof. Dr. Ulrich Schubert is named a 2016 Highly Cited Researcher.

He was selected as a Highly Cited Researcher because his work has been identified as being among the most valuable and significant in the field. His reports rank among the top 1% most cited works for his subject field and year of publication, earning them the mark of exceptional impact.

More information about citations of Prof. Dr. Schubert.




Angewandte Chemie Publication

Publication in the leading chemistry journal "Angewandte Chemie" (Angew. Chem. Int. Ed. 2016, 55, 14427) "Redox-flow batteries (RFB) can easily store large amounts of electric energy and thereby mitigate the fluctuating output of renewable power plants. They are widely discussed as energy-storage solutions for wind and solar farms to improve the stability of the electrical grid. Most common RFB concepts are based on strongly acidic metal-salt solutions or poorly performing organics. Herein we present a battery which employs the highly soluble N,N,N-2,2,6,6-heptamethylpiperidinyl oxy-4-ammonium chloride (TEMPTMA) and the viologen derivative N,N′-dimethyl-4,4-bipyridinium dichloride (MV) in a simple and safe aqueous solution as redox-active materials. The resulting battery using these electrolyte solutions has capacities of 54 Ah L−1, giving a total energy density of 38 Wh L−1 at a cell voltage of 1.4 V. With peak current densities of up to 200 mA cm−2 the TEMPTMA/MV system is a suitable candidate for compact high-capacity and high-power applications."


link to abstract


Die SmartDyeLivery GmbH konnte bei dem diesjährigen Thüringer Innovationspreises überzeugen.

"Das Unternehmen wird in den kommenden Jahren eine zum Patent angemeldete, innovative Technologieplattform für den gezielten Transport von Wirkstoffen in bestimmte Zellen des Körpers auf den Markt bringen. Der Wirkstofftransport erfolgt mit funktionalisierten Nanopartikeln, winzigen Kugeln, die mit Hilfe von Farbmolekülen zielgerichtet zu den erkrankten Bereichen des Körpers navigieren und nur dort ihren Wirkstoff kontrolliert freisetzen."

Mehr Informationen finden Sie hier.